Fmr LLC Has $119.54 Million Position in Repligen Co. (NASDAQ:RGEN)

FMR LLC reduced its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 44.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 803,269 shares of the biotechnology company's stock after selling 641,519 shares during the period. FMR LLC owned about 1.43% of Repligen worth $119,542,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Toronto Dominion Bank grew its holdings in shares of Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 75 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock worth $982,000 after buying an additional 89 shares during the period. Ballentine Partners LLC lifted its stake in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock valued at $269,000 after buying an additional 105 shares during the last quarter. Diversified Trust Co boosted its holdings in shares of Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after acquiring an additional 106 shares during the period. Finally, CWM LLC grew its position in shares of Repligen by 36.3% during the third quarter. CWM LLC now owns 428 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 114 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on RGEN. Royal Bank of Canada restated an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating for the company. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a report on Friday, November 22nd. Finally, Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective for the company. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $190.25.

Repligen Price Performance

RGEN stock traded down $6.83 on Thursday, hitting $142.26. 443,658 shares of the company's stock traded hands, compared to its average volume of 661,336. The stock has a market cap of $7.97 billion, a price-to-earnings ratio of -384.48, a P/E/G ratio of 4.47 and a beta of 0.96. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average of $141.38 and a 200-day moving average of $142.15.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 EPS. On average, analysts forecast that Repligen Co. will post 1.52 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.